Sunday, October 11, 2026

Monetary Policy Impact

2 articles

Fed Rate Cut Odds Drop to 51% by June as Powell Signals Extended Pause

Fed Rate Cut Odds Drop to 51% by June as Powell Signals Extended Pause

Markets now price just a 51% chance of a single Fed rate cut by June 2026, down sharply from earlier expectations, as Chair Powell emphasizes preventing tariff-driven inflation from becoming entrenched. Multiple Fed officials signal policy rates are near neutral, with sticky services inflation reinforcing a prolonged pause in the easing cycle that began in 2024.

ViaNews Editorial Team (Markets)•
Fed Holds Rates Through 2026 Despite 2025 Cuts as Confidence in Soft Landing Grows

Fed Holds Rates Through 2026 Despite 2025 Cuts as Confidence in Soft Landing Grows

The Federal Reserve projects no interest rate cuts in 2026 following anticipated reductions in late 2025, signaling confidence in economic resilience. Atlanta Fed President Raphael Bostic forecasts an extended holding period while Richmond's Tom Barkin cites fading uncertainty and improving outlook. The shift drove 10-year Treasury yields from -0.6 to 6.25 benchmark points.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com